表格6-K
美國證券及交易所委員會
華盛頓特區20549
外國私人發行人報告
根據第13a-16或第15d-16條規則
1934年證券交易所法案
2024年10月
委員會檔案編號：001-38757
武田製藥有限公司
(註冊人名稱之英文翻譯)
日本橋本町二丁目1-1
東京103-8668中央區
日本
(總部辦公地址)
請勾選表明登記人是否提交或將提交以20-F表或40-F表作封面的年度報告。
20-F表格 ☒ 40-F表格 ☐
如果申報人根據條例 S-T 規則 101(b)(1) 允許，以紙本方式提交表格 6-K，請打勾： ☐
如果發出申報書6-K是根據Regulation S-T Rule 101(b)(7)允許的紙上提交，請用勾選印記表示： ☐
此表格提供的資訊：
展覽
簽名
根據《證券交易法》的要求，申報人已經授權簽署此報告，且得到了授權。
| 武田製藥有限公司 | |||||||||||
| 日期：2024年10月31日 | 作者： | /s/ 武田典政 | |||||||||
武田典政 首席會計官和公司控制器 | |||||||||||
新聞公告
關於2024財年（IFRS）合併財務預測修正的通知
2024年10月31日，日本大阪 武田（TSE：4502 / 紐交所：TAK）今日宣佈了截至2025年3月31日（FY2024）的全年合併財務預測修訂如下。
1.截至2025年3月31日財政年度終了時的全年綜合財務預測已修訂
(百萬日元)
營業收入 | 營運 利潤 | 營業收入之前 所得稅前獲利 | 應歸屬凈利潤 原本擁有者的 該公司 | 基本盈利 每股盈利 | |||||||||||||
原始預測 (A)* | 4,350,000 | 225,000 | 55,000 | 58,000 | 36.70日圓 | ||||||||||||
修訂預測 (B) | 4,480,000 | 265,000 | 93,000 | 68,000 | 43.03日圓 | ||||||||||||
差異 (B-A) | 130,000 | 40,000 | 38,000 | 10,000 | ― | ||||||||||||
更改 % | 3.0% | 17.8% | 69.1% | 17.2% | ― | ||||||||||||
* 2024年5月9日宣布。
(百萬日元)
核心營收 | 核心 營運 利潤 | 核心每股收益 | |||||||||
原始預測（A）* | 4,350,000 | 1,000,000 | 431 日元 | ||||||||
修訂預測（B） | 4,480,000 | 1,050,000 | 456日圓 | ||||||||
（b-A）的差異 | 130,000 | 50,000 | ― | ||||||||
更改 % | 3.0% | 5.0% | ― | ||||||||
* 2024年5月9日宣布。
（注意）有關核心財務指標的定義，請參閱附於盈利報告的財務附錄中的「非IFRS財務指標及美元方便換算的定義和解釋」。
2.修訂原因
武田預計2024年的營業收入將達到44800億日元，比原先預測增加1300億日元，增幅為3.0%。主要原因是在美國Vyvanse失去專利後，所預期的通用藥物侵蝕較輕微，以及其他業務動能以及對外匯匯率假設的整體有利變化。
核心營業收入預測已經以與營業收入預測相同的方式進行修訂。
預計營業利潤將從原始預測的JPY 2650億增加JPY 400億，增長17.8％，這反映了由於美國低於預期的通用侵蝕對VYVANSE產生的积极影响。 其他產品、增量營業費用和外幣匯率的不利影響部分抵銷了這一增長。
核心營業利潤，不包括與武田核心業務趨勢和業務表現無關的影響，預計達到1.05兆日圓，增加5百億日圓，增幅為5.0%。
預計本年度凈利潤（歸屬於公司股東）將達到680億日元，較原始預測增加100億日元，增幅為17.2%。預計稅前利潤將增加380億日元，增幅為69.1%，主要反映營業利潤的增加。儘管預計這種稅前利潤增加將部分被較高的稅費抵銷，主要是由於递延稅資產減值所致，導致預期有效稅率約為27%。
預計每股收益為JPY 43.03，增加JPY 6.33，即17.2％，核心每股收益預計為JPY 456，增加JPY 26，即5.9％。
3.管理指引 至2025年3月31日止財政年度
武田以在恆定匯率（CER）基礎上的核心營收、核心營業利潤和核心每股收益變化作為其管理指引。截至2025年3月31日（截至2024年度）的整年管理指引已從2024年5月9日公布的原管理指引進行修訂，具體如下：
CER變動%
原始管理指導 (2024年5月9日) | 修訂後管理指導 (2024年10月31日) | |||||||
核心營收 | 持平至稍微下降 | 持平至稍微增加 | ||||||
核心營業利潤 | 大約下跌百分之十 | 中位數字百分之幾下跌 | ||||||
核心每股收益 | 中位數字十位百分之幾下跌 | 大約下跌百分之十 | ||||||
有關武田藥品的事項
武田致力於為人們創造更健康的生活和更美好的未來。我們的目標是在消化道和炎症、罕見疾病、血漿衍生治療、腫瘤學、神經科學和疫苗等核心治療和業務領域發現和提供改變生活的治療方法。與我們的合作夥伴共同努力，通過我們豐富多樣的管線改善患者體驗，推動治療期權的新領域。作為一家以價值為基礎、以研發為驅動的生物製藥公司，總部位於日本，我們以對患者、我們的人員和地球的承諾為指導。我們在大約80個國家和地區擁有員工，他們受我們的宗旨驅使，承擔了已經為我們定義了兩個世紀的價值觀。欲瞭解更多信息，請造訪 www.takeda.com.
聯絡人
投資者關係 克里斯多福·奧賴利 christopher.oreilly@takeda.com +81 (0) 3-3278-2543 | 媒體聯繫 布倫丹·詹寧斯 brendan.jennings@takeda.com +81 (0) 80-2705-8259 (在 日本 業務時間之外) M媒體關係media_relations@takeda.com | ||||
重要通知
就本通知而言，“新聞稿”指的是本文件、任何口頭發表、任何問答環節以及武田製藥公司（“武田”）有關本新聞稿的任何書面或口頭材料。本新聞稿（包括任何口頭簡報以及相關之問答環節）並非旨在構成、代表或成為任何要約、邀請或徵求購買、另行取得、認購、交換、賣出或其他處置任何證券的一部分或其中。本新聞稿中並未透露任何股份或其他證券以供公眾認購。除依據已修訂的1933年美國證券法或其豁免條款登記之情況外，不得透過本新聞稿在美國進行證券發行。本新聞稿之提供（連同可能提供予接收者的任何進一步資訊）須受其僅供接收者僅供信息之條件控制（並非用於評估任何投資、收購、處置或任何其他交易）。任何不遵守這些限制可能構成對適用證券法的違反。
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or
any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Financial Information and Non-IFRS Measures
Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).
This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our investor presentation of our Q2 FY2024 financial results (available at www.takeda.com/investors).
The usefulness of Core Financial Measures to investors has significant limitations including, but not limited to, (i) they are not necessarily identical to similarly titled measures used by other companies, including those in the pharmaceutical industry, (ii) they exclude financial information and events, such as the effects of non-cash expenses such as dispositions or amortization of intangible assets, that some may consider important in evaluating Takeda’s performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future (however, it is Takeda’s policy not to adjust out normal, recurring cash operating expenses necessary to operate our business) and (iv) they may not include all items which investors may consider important to an understanding of our results of operations, or exclude all items which investors may not consider to be so.
###